Plain-English translation of NCT05503134 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new approach to treat relapsed or hard-to-treat acute myeloid leukemia (AML) in children and young adults. The treatment combines standard chemotherapy drugs (fludarabine and cytarabine) with special immune cells called natural killer cells that are grown in the lab and come from healthy donors. Researchers want to see if this combination can help fight the leukemia when it has come back or didn't respond to earlier treatment.
Young people whose leukemia comes back or doesn't respond to standard chemotherapy have very limited treatment options and poor survival rates. This medication aims to give their immune system a boost to fight the cancer more effectively, offering hope for patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You will first receive chemotherapy for 5 days, then receive six doses of the immune cells given three times a week over two weeks. Depending on how well the treatment works, you may receive a second round of the same treatment. Throughout the study, you will have frequent blood tests, bone marrow tests, and clinic visits to monitor how you are responding and check for any side effects. The entire treatment period typically lasts several weeks, with follow-up visits to track your long-term recovery.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States